Roche In Drug Discovery Deal With Jnana Therapeutics

Jnana Therapeutics, a privately held company focused on chemo-proteomics platform, said on Tuesday that it has inked a collaboration and license deal with Roche Holding AG (RHHBY), to discover small molecule drugs directed to target across a diverse range of target classes in cancer, immune-mediated and neurological illnesses.

The collaboration allows Jnana to conduct discovery and preclinical activities against multiple cancer, immune-mediated and neurological disease targets, whereas Roche will develop and commercialize final products.

According to the deal, Jnana will obtain an upfront payment of $50 million and additional potential future milestone payments that could exceed $2 billion, as well as tiered royalties.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT